BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) invests in, manages and commercializes biomedical innovations grouped into “clusters” around defined medical conditions. The two current clusters are in ophthalmology via 100% ownership of XLVision Sciences, and in cancer diagnostics via a 39.6% controlling ownership of Micromedic Technologies (TASE: MCTC). XLVision technologies include IOPtimate™, a laser-based noninvasive surgical treatment for glaucoma; TeaRx, a point-of-care dry-eye syndrome diagnostic test; and Eye-D®, a long-term controlled release drug-delivery implant platform. Micromedic diagnostic tests are designated for colorectal, cervical, breast, bladder, lung and other cancers. SNNLive spoke with Suzana Zahum Zilberberg, CEO of BioLight Life Sciences Investments Ltd. at the Healthcare Media Day 2015 in San Francisco, CA.
She begins with what the company is focusing on in their business model, “We do have, today, two clusters, one of them is around ophthalmology. Until yesterday, we dealt with glaucoma and dry eye and yesterday we announced that we will invest in additional – actually we invested, in additional company focusing on drug development for the back of the eye...and the other cluster is dealing with cancer diagnostics. So you will see in our operation units diagnostics, medical device and drugs together.
Mrs. Zilberberg explains how Biolight differs from incubators, “We do incorporate companies that are in the early stages like the incubators, but also in late stages, so for each of our clusters we already have commercial available product. In ophthalmology group, we do have a laser base medical device for glaucoma surgery. In our cancer diagnostic cluster we just started selling cervical cancer diagnostics kit. So we do have early-stage and late-stage companies together.”
She then goes into what products Biolight has in the US and what to look forward to, “We have some exciting product that are already here in the US, so for example, we have an implant that knows how to control-release eye drops over time. We are currently conducting a clinical trial here in the US in nine different centers, which is under a 545BII regulatory pathway under FDA of course. Everything is being done here in the US from manufacturing to clinical trial. We just finished another clinical trial with a diagnostic tool for dry eye which we will publish the results next week.”
“First of all they must have exciting technologies, technologies that give solution to unmet needs. So it’s not me too or me better, it’s really something that is innovative in you. Second of all, they cannot compete with existing technologies that we have in our cluster. One of the most important things in our business model is to interact between the technologies and if you have competing technologies you won’t be able to do that. We can invest in early stage companies, we can invest in late stage companies, we are looking for economic model, which would be good, we are looking for good managerial team that will contribute to our cluster approach and we are looking for exciting products,” Mrs. Zilberberg concludes. For more information, check out their website: www.Bio-Light.co.il
© 2017 Stock News Now
Supported by Superior Web Solutions